Processes to make neosaxitoxin and analogues thereof

Patent metadata

Field	Value
Publication number	US-11566271-B2
Application number	US-202017074607-A
Country	US
Kind code	B2
Filing date	Oct 19, 2020
Priority date	Feb 12, 2016
Publication date	Jan 31, 2023
Grant date	Jan 31, 2023

Abstract

The present invention relates to processes to make neosaxitoxin, and analogues and variants thereof, and intermediates in the production of neosaxitoxin in recombinant host cells. Neosaxitoxin and the analogues and variants thereof may be used in the production of pharmaceutical compositions.

First claim

The invention claimed is:

1. A process for producing a neosaxitoxin analogue or variant, the process comprising the steps:
(A) contacting the substrates:
(i)S-adenosylmethionine,
(ii) arginine
(iii) acetyl-CoA, malony-CoA or propionyl-CoA, and
(iv) carbamoyl phosphate,

with Sxt A, B, D, G, H, I, S, T, U, V, W and X polypeptides, in a reaction medium, wherein the reaction medium additionally comprises a PPTase, and optionally
(B) isolating and/or purifying a neosaxitoxin analogue or variant from the reaction medium,
wherein the neosaxitoxin analogue or variant is:
(I) gonyautoxin 1 or gonyautoxin 4, and the substrates (i)-(iv) are additionally contacted with Sxt DIOX and Sxt SUL;
(II) saxitoxin, and the substrates (i)-(iv) are not contacted with Sxt X;
(III) gonyautoxin 2 or gonyautoxin 3, and the substrates (i)-(iv) are additionally contacted with Sxt DIOX and Sxt SUL, and the substrates (i)-(iv) are not contacted with Sxt X;
(IV) gonyautoxin 5, and the substrates (i)-(iv) are additionally contacted with Sxt N, and the substrates (i)-(iv) are not contacted with Sxt X; or
(V) Lyngbya wollei toxin, and the substrates (i)-(iv) are additionally contacted with Sxt ACT, and the substrates (i)-(iv) are not contacted with Sxt X.

2. A process for producing a neosaxitoxin analogue or variant in a host cell, the process comprising the steps:
(A) culturing a host cell which comprises nucleic acid molecules encoding the Sxt polypeptides A, B, D, G, H, I, S, T, U, V, W and X in a culture medium in the presence of the substrates:
(i)S-adenosylmethionine,
(ii) arginine
(iii) acetyl-CoA, malony-CoA or propionyl-CoA, and
(iv) carbamoyl phosphate,

and wherein the host cells do not comprise nucleic acid molecules encoding one or more of Sxt polypeptides Q, R and ORF24,
under conditions which are suitable for the production of a neosaxitoxin analogue or variant; and optionally
(B) isolating and/or purifying the neosaxitoxin analogue or variant from the host cells or from the culture medium,
wherein the neosaxitoxin analogue or variant is:
(I) gonyautoxin 1 or gonyautoxin 4, and the host cell additionally comprises nucleic acid molecules encoding Sxt DIOX and Sxt SUL;
(II) saxitoxin, and the host cell does not comprise a nucleic acid molecule encoding Sxt X;
(III) gonyautoxin 2 or gonyautoxin 3, and the host cell additionally comprises nucleic acid molecules encoding Sxt DIOX and Sxt SUL, and the host cell does not comprise a nucleic acid molecule encoding Sxt X;
(IV) gonyautoxin 5, and the host cell additionally comprises a nucleic acid molecule encoding Sxt N, and the host cell does not comprise a nucleic acid molecule encoding Sxt X; or
(V) Lyngbya wollei toxin, and the host cell additionally comprises a nucleic acid molecule encoding Sxt ACT, and the host cell does not comprise a nucleic acid molecule encoding Sxt X.

3. A process as claimed in claim 2 , wherein the host cell comprises an additional nucleic acid molecule encoding a phosphopantetheinyl transferase (PPTase).

4. A process as claimed in claim 2 , wherein the host cells do not comprise nucleic acid molecules encoding one or more of the Sxt polypeptides C, J and K.

5. A process as claimed in claim 1 , wherein the substrates are not contacted with one or more of the Sxt polypeptides Q, R and ORF24.

6. A process as claimed in claim 2 , wherein the host cells do not comprise nucleic acid molecules encoding any of the said Sxt polypeptides in one or more of (a)-(c):
(a) C, Q, R and ORF24;
(b) L, Q, R and ORF 24; or
(c) J, K, L, Q, R and ORF 24.

7. A process as claimed in claim 2 , wherein the host cells do not comprise nucleic acid molecules encoding one or more of Sxt polypeptides F, M and P.

8. A process as claimed in claim 2 , wherein the host cells additionally comprise nucleic acid molecules encoding one or more of Sxt polypeptides C, E, J, K, L, and R.

9. A process as claimed in claim 2 , wherein the host cells do not comprise nucleic acid molecules encoding one or more of Sxt polypeptides F, M, N, O, P, Y, Z, ORF3, ORF4, ORF29, ORF34, OMPR or HISA,
wherein the neosaxitoxin analogue or variant is:
(I) gonyautoxin 1 or gonyautoxin 4, and the substrates (i)-(iv) are additionally contacted with Sxt DIOX and Sxt SUL, and/or the host cell additionally comprises nucleic acid molecules encoding Sxt DIOX and Sxt SUL;
(II) saxitoxin, and the substrates (i)-(iv) are not contacted with Sxt X and/or the host cell does not comprise a nucleic acid molecule encoding Sxt X;
(III) gonyautoxin 2 or gonyautoxin 3, and the substrates (i)-(iv) are additionally contacted with Sxt DIOX and Sxt SUL, and the substrates (i)-(iv) are not contacted with Sxt X and/or the host cell additionally comprises nucleic acid molecules encoding Sxt DIOX and Sxt SUL, and the host cell does not comprise a nucleic acid molecule encoding Sxt X; or
(V) Lyngbya wollei toxin, and the substrates (i)-(iv) are additionally contacted with Sxt ACT, and the substrates (i)-(iv) are not contacted with Sxt X and/or the host cell additionally comprises a nucleic acid molecule encoding Sxt ACT, and the host cell does not comprise a nucleic acid molecule encoding Sxt X.

10. A process as claimed in claim 2 , wherein the host cell is a recombinant prokaryotic host cell, where the prokaryotic cell is an E. coli cell.

11. A process as claimed in claim 2 , wherein the host cell is a heterotroph.

12. A process as claimed in claim 2 , wherein the host cell is a recombinant yeast cell.

13. A process as claimed in claim 2 , wherein the neosaxitoxin analogue or variant, or a pharmaceutically acceptable salt thereof, is formulated into a pharmaceutical composition.

14. A process as claimed in claim 13 , wherein the formulating step comprises admixing isolated or purified neosaxitoxin analogue or variant with one or more pharmaceutically-acceptable carriers, adjuvants and/or excipients.

15. A host cell which comprises nucleic acid molecules coding for the Sxt polypeptides A, B, D, G, H, I, S, T, U, V, W and X, wherein the host cell does not comprise nucleic acid molecules coding for:
(i) one or more of the Sxt polypeptides C, J or K;
(ii) one or more of the Sxt polypeptides Q, R and ORF24;
(iii) one or more of the Sxt polypeptides C, Q, R and ORF24;
(iv) one or more of the Sxt polypeptides L, Q, R and ORF 24;
(v) one or more of the Sxt polypeptides J, K, L, Q, R and ORF 24; or
(vi) one or more of the Sxt polypeptides F, M and P,

wherein the host cell:
(I) additionally comprises nucleic acids encoding Sxt DIOX and Sxt SUL;
(II) does not comprise a nucleic acid encoding Sxt X;
(III) additionally comprises nucleic acids encoding Sxt DIOX and Sxt SUL, and does not comprise a nucleic acid encoding Sxt X;
(IV) additionally comprises a nucleic acid encoding Sxt N, and does not comprise a nucleic acid encoding Sxt X; or
(V) additionally comprises a nucleic acid encoding Sxt ACT, and does not comprise a nucleic acid encoding Sxt X.

16. A host cell as claimed in claim 15 , wherein the host cell 1) does not comprise nucleic acid molecules coding for one or more of the Sxt polypeptides F, M and P and 2) comprises nucleic acid molecules coding for one or more Sxt polypeptides selected from the group consisting of Sxt C, E, J, K, L, and/or R.

17. A host cell as claimed in claim 15 , wherein the host cell does not comprise nucleic acid molecules coding for one or more of the Sxt polypeptides selected from the group consisting of F, M, N, O, P, Y, Z, ORF3, ORF4, ORF29, ORF34, OMPR or HISA,
wherein the ho

Assignees

• Vestlandets Innovasjonsselskap As
• Newsouth Innovations Pty Ltd
• Vestlandets Innovasjonsseiskap AS

Inventors

• Kellmann Ralf
• Neilan Brett

Classifications

• C12N2500/42

  Organic phosphate, e.g. beta glycerophosphate · CPC title

• C12N2500/32

  Amino acids · CPC title

• C12R2001/19

  Escherichia coli · CPC title

• C12N15/52

  Genes encoding for enzymes or proenzymes · CPC title

• C12N15/70

  Vectors or expression systems specially adapted for E. coli · CPC title